Celltrion Pharm Inc. (068760) Financial Statements

― Followers

Celltrion Pharm Inc. Financial Overview

Celltrion Pharm Inc.'s market cap is currently ₩1.70T. The company's EPS TTM is ₩882.94; its P/E ratio is 39.90; and it has a dividend yield of 0.40%. Celltrion Pharm Inc. is scheduled to report earnings on August 14, 2026, and the estimated EPS forecast is ₩―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	₩ 536.40B	₩ 477.84B	₩ 388.79B	₩ 386.04B	₩ 398.74B
Gross Profit	₩ 163.78B	₩ 122.01B	₩ 119.71B	₩ 112.77B	₩ 119.25B
Operating Income	₩ 56.09B	₩ 37.22B	₩ 36.07B	₩ 38.17B	₩ 47.80B
EBITDA	₩ 78.63B	₩ 57.36B	₩ 54.22B	₩ 54.10B	₩ 64.26B
Net Income	₩ 38.75B	₩ 21.97B	₩ 21.26B	₩ 25.96B	₩ 34.58B
Balance Sheet
Cash & Short-Term Investments	₩ 116.93B	₩ 69.60B	₩ 37.13B	₩ 49.07B	₩ 88.16B
Total Assets	₩ 759.44B	₩ 669.46B	₩ 641.64B	₩ 599.72B	₩ 637.88B
Total Debt	₩ 161.31B	₩ 172.17B	₩ 162.53B	₩ 160.70B	₩ 181.03B
Net Debt	₩ 111.44B	₩ 126.69B	₩ 142.82B	₩ 129.31B	₩ 100.85B
Total Liabilities	₩ 323.48B	₩ 272.54B	₩ 264.98B	₩ 242.94B	₩ 305.92B
Stockholders' Equity	₩ 435.96B	₩ 396.92B	₩ 376.67B	₩ 356.79B	₩ 331.97B
Cash Flow
Free Cash Flow	₩ 68.51B	₩ 50.61B	₩ 1.86B	₩ -10.33B	₩ 80.65B
Operating Cash Flow	₩ 86.43B	₩ 56.59B	₩ 8.76B	₩ -4.05B	₩ 93.15B
Investing Cash Flow	₩ -57.54B	₩ -12.12B	₩ -4.22B	₩ -14.57B	₩ -16.30B
Financing Cash Flow	₩ -24.50B	₩ -18.71B	₩ -16.21B	₩ -30.18B	₩ -22.41B

Currency in KRW

Celltrion Pharm Inc. Earnings and Revenue History

Income Statement >

Celltrion Pharm Inc. Debt to Assets

Balance Sheet >

Celltrion Pharm Inc. Cash Flow

Cash Flow >

Celltrion Pharm Inc. Forecast EPS vs Actual EPS

Earnings >